ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 35,256,656 shares, a growth of 3.7% from the November 15th total of 34,003,445 shares. Currently, 27.6% of the shares of the company are sold short. Based on an average daily trading volume, of 1,934,456 shares, the days-to-cover ratio is presently 18.2 days.

In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the purchase, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ZIOP. Chevy Chase Trust Holdings Inc. purchased a new stake in ZIOPHARM Oncology in the 3rd quarter worth approximately $104,000. Amalgamated Bank lifted its stake in ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 6,000 shares in the last quarter. BB&T Securities LLC purchased a new stake in ZIOPHARM Oncology in the 2nd quarter worth approximately $112,000. Finally, Adell Harriman & Carpenter Inc. purchased a new stake in ZIOPHARM Oncology in the 3rd quarter worth approximately $141,000. Institutional investors and hedge funds own 40.25% of the company’s stock.

ZIOP has been the topic of a number of recent research reports. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. HC Wainwright restated a “buy” rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Friday, November 10th. Finally, Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $12.58.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.44 on Thursday. ZIOPHARM Oncology has a 52 week low of $3.90 and a 52 week high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was up .0% compared to the same quarter last year. analysts anticipate that ZIOPHARM Oncology will post -0.54 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/14/ziopharm-oncology-inc-ziop-short-interest-up-3-7-in-november.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Stock Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related stocks with our FREE daily email newsletter.